NeoTX Therapeutics is a biopharmaceutical company focused on developing late-stage anti-cancer drugs through oncology immunotherapy research. The company addresses the need for more effective cancer treatments by leveraging predictive therapeutic approaches to enhance patient outcomes.
Funding
$45M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers develop resistance to existing treatments, and new therapeutic approaches are needed to improve patient outcomes. Traditional cancer treatments often lack precision, leading to systemic toxicity and limited efficacy in certain patient populations.
Solution
NeoTX Therapeutics is developing late-stage anti-cancer drugs using an oncology immunotherapy approach. The company focuses on predictive therapeutic strategies to identify and develop treatments that are more likely to be effective for specific patient subgroups. By leveraging predictive biomarkers and advanced research, NeoTX aims to create targeted therapies that enhance the body's immune response to cancer cells, leading to improved outcomes and reduced side effects.
Target Audience
The primary target audience includes cancer patients, oncologists, and healthcare providers seeking more effective and targeted cancer treatments.
Features
- Development of late-stage anti-cancer drugs
- Focus on oncology immunotherapy
- Predictive therapeutic approaches to enhance patient outcomes